Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2024


	Three months ended
	March 31,
	2024		2023
Revenue	$	5,678	$	47,601
Less:
Research		(3,800)		(3,500)
CMC and Quality		(14,200)		(14,300)
Biomarkers		(2,500)		(1,200)
Development and Compliance		(12,600)		(9,200)
Infrastructure management and Facilities		(7,700)		(6,200)
Commercial planning		(2,600)		(1,100)
Support functions		(9,000)		(13,600)
Other segment expenses^(a)		(2,539)		3,155
Total operating expenses		(54,939)		(45,945)
Operating (loss)/profit		(49,261)		1,656

Interest income		1,345		676
Other income (expense), net		(61)		(671)
Income tax expense		(526)		(625)
Segment and consolidated net (loss)/profit	$	(48,503)	$	1,036